Continuing Enhanced National Surveillance for Prion Diseases in the United States

Forecasted opportunity (not yet open for applications; expected to be posted around 2026-12-29; estimated application due date 2027-03-27). The CDC announces the availability of FY 2027 funds for a cooperative agreement to continue enhanced national surveillance for human prion diseases, also known as transmissible spongiform encephalopathies (TSEs), in the United States. The purpose is to continue an active surveillance program to help confirm suspected and clinically diagnosed cases of human prion disease and to monitor the occurrence of potentially emerging human prion diseases in the United States. Outcomes are enhanced national surveillance for always fatal human prion diseases through improved diagnoses and continued monitoring for emerging or new prion diseases in the United States. These outcomes are accomplished through the funding of a specialized center to conduct state-of-the-art diagnostic techniques. Prion diseases can only be confirmed through brain tissue analyses, and many facilities lack the expertise and/or the willingness, due to infection control concerns, to handle and accurately diagnose specimens from suspected cases. Since 1997, the Centers for Disease Control and Prevention (CDC) has funded a center to provide prion disease diagnostic services, which has allowed for disease confirmation, evaluation of disease trends over time, and identification of disease subtypes. Data have been shared with CDC experts who partner with center staff, providing guidance and epidemiological knowledge. This collaboration has contributed to accurate national surveillance findings and helped to provide confidence that novel prion diseases, such as a human form of the animal prion disease, chronic wasting disease, have not been occurring in the country.